-
Ionis Pharmaceuticals NASDAQ:IONS For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Its scientific innovation began and continues with the knowledge that sick people depend on it, which fuels its vision of becoming one of the most successful biotechnology companies.
Location: 2855 Gazelle Ct, California, 92010-6670, US | Website: www.ionispharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
4.991B
Cash
2.491B
Avg Qtr Burn
-87.99M
Short % of Float
6.96%
Insider Ownership
0.85%
Institutional Own.
-
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TRYNGOLZA™ (olezarsen) Details Familial chylomicronemia syndrome | Approved Update | |
QALSODY™ (Tofersen) Details Amyotrophic lateral sclerosis | Approved Update | |
WAINUA™ Eplontersen (AKCEA-TTR-LRx) Details Transthyretin amyloidosis | Approved Quarterly sales | |
SPINRAZA Details Spinal muscular atrophy | Approved Quarterly sales | |
Donidalorsen (IONIS-PKK-LRx) Details Hereditary angioedema | PDUFA Approval decision | |
Ulefnersen (ION363 ) Details Amyotrophic lateral sclerosis | Phase 3 Data readout | |
Bepirovirsen (IONIS-HBVRx) Details Hepatitis B | Phase 3 Data readout | |
Eplontersen (AKCEA-TTR-LRx) Details Diabetic cardiomyopathy, Transthyretin amyloidosis, Transthyretin Amyloid Cardiomyopathy | Phase 3 Data readout | |
IONIS-APOCIII-LRx (Olezarsen) Details Severe hypertriglyceridemia | Phase 3 Data readout | |
Pelacarsen Details Heart disease, Cardiovascular disease | Phase 3 Data readout | |
Zilganersen (ION373) Details Alexander Disease | Phase 3 Data readout | |
ION582 Details Angelman Syndrome | Phase 3 Initiation | |
ION839 / AZD2693 Details Non-alcoholic steatohepatitis | Phase 2b Data readout | |
ION224 Details Non-alcoholic steatohepatitis | Phase 2b Update | |
IONIS-MAPTRx (BIIB080) Details Alzheimer's disease | Phase 2 Data readout | |
Tominersen (IONIS-HTT Rx) Details Huntington's disease | Phase 2 Update | |
IONIS-AGT-LRx Details Heart failure, Pulmonary hypertension | Phase 2 Update | |
IONIS-FB-LRx Details IgA nephropathy | Phase 2 Update | |
IONS356 (PLP1) Details Pelizaeus-Merzbacher disease | Phase 1/2 Data readout | |
IONIS-FB-LRx Details Geographic atrophy | Failed Discontinued | |
Cimdelirsen (IONIS-GHR-LRx) Details Acromegaly | Failed Discontinued | |
IONIS-ENaC-2.5Rx (antisense medicine) Details Cystic fibrosis | Failed Discontinued | |
Fesomersen (IONIS-FXI-LRx) Details Hepatitis B | Failed Discontinued |